Eli Lilly (LLY) reported mostly worse-than-expected fourth-quarter results Thursday, but the drugmaker's adjusted profit came in above estimates.
Eli Lilly reported net income of $4.41 billion, or $4.88 per share, on revenue of $13.53 billion. Analysts had expected profit of $4.52 billion, or $4.99 per share, on $13.56 billion in revenue, per Visible Alpha.
After adjusting for one-time costs, Eli Lilly's adjusted earnings per share (EPS) of $5.32 topped expectations of $5.11.
Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound grew to $3.53 billion and $1.91 billion, respectively, below expectations of $3.65 billion and $2.04 billion.
Eli Lilly said it expects 2025 revenue between $58.0 to $61.0 billion, with EPS from $22.05 to $23.55, and adjusted EPS of $22.50 to $24.00. Those ranges are largely in line with or above expectations.
The results come one day after rival Novo Nordisk (NVO), the Danish company behind weight-loss drugs Ozempic and Wegovy, topped estimates in its fourth-quarter report.
Eli Lilly shares were up more than 2% immediately following the report. They entered the day up about 20% over the last 12 months. By contrast, Novo Nordisk shares are down about 25% in the past year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.